Charles River Laboratories International, Inc.
CRL- Exchange
- NYSE
- Industry
- Services-Commercial Physical & Biological Research
- SEC CIK
- 0001100682
In the last 90 days, Charles River Laboratories International, Inc. insiders filed 0 open-market purchases and 9 sales; 569 institutions reported holding it in 13F filings for Q2 2026, worth $12.9B in total; Harris Associates (Oakmark) is the only superinvestor holding it.
13F holders, Q1 2022
Institutional positions in Charles River Laboratories International, Inc. as of Mar 31, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 644
- −56 vs. Q4 2021
- Shares held
- 47.6M
- +427.2K (+0.9%) vs. Q4 2021
- Total value
- $13.5B
- −$4.25B (−24.0%) vs. Q4 2021
- New holders
- 60
- 262 more added
- Sold out
- 116
- 234 more reduced
8 institutions that held it in Q4 2021 haven't filed for Q1 2022 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting CRL on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 569 | $12.9B |
| Q1 2026 | 560 | $9.86B |
| Q4 2025 | 584 | $10.6B |
| Q3 2025 | 556 | $7.92B |
| Q2 2025 | 519 | $7.73B |
| Q1 2025 | 562 | $8.03B |
| Q4 2024 | 636 | $9.78B |
| Q3 2024 | 629 | $10.3B |
| Q2 2024 | 665 | $10.8B |
| Q1 2024 | 675 | $14.1B |
| Q4 2023 | 634 | $12.3B |
| Q3 2023 | 622 | $10.1B |
| Q2 2023 | 613 | $10.7B |
| Q1 2023 | 623 | $10.3B |
| Q4 2022 | 630 | $10.8B |
| Q3 2022 | 583 | $9.91B |
| Q2 2022 | 629 | $10.4B |
| Q1 2022 | 644 | $13.5B |
| Q4 2021 | 708 | $17.8B |
| Q3 2021 | 679 | $19.3B |
| Q2 2021 | 639 | $17.6B |
| Q1 2021 | 562 | $13.7B |
Institutions, Q1 2022
Shares, value and share of portfolio for each institution holding Charles River Laboratories International, Inc.; share changes are against Q4 2021.